The Negative Impact of Cancer Cell Nitric Oxide on Photodynamic Therapy. Methods Mol Biol 2022;2451:21-31
Date
05/04/2022Pubmed ID
35505007DOI
10.1007/978-1-0716-2099-1_2Scopus ID
2-s2.0-85129667244 (requires institutional sign-in at Scopus site)Abstract
Numerous studies have shown that low-flux nitric oxide (NO) in tumors produced mainly by inducible nitric oxide synthase (iNOS/NOS2) can signal for angiogenesis, inhibition of apoptosis, and promotion of cell growth, migration, and invasion. Studies in the authors' laboratory have revealed that iNOS-derived NO in various cancer cell types elicits resistance to cytotoxic photodynamic therapy (PDT) and moreover endows PDT-surviving cells with more aggressive proliferation and migration/invasion. In this chapter, we describe how cancer cell iNOS/NO in vitro can be monitored in different PDT model systems (e.g., a targeted cell-bystander cell model) and how pharmacologic interference with basal and PDT-upregulated iNOS/NO can significantly improve PDT outcomes.
Author List
Fahey JM, Girotti AWAuthor
Albert Girotti PhD, MS Emeritus Professor in the Biochemistry department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
ApoptosisCell Proliferation
Humans
Neoplasms
Nitric Oxide
Photochemotherapy
